PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Zhang, W. [1 ]
Zhao, W. [1 ]
Liu, J. [1 ]
He, A. [1 ]
Chen, Y. [1 ]
Cao, X. [1 ]
Yang, N. [1 ]
Wang, B. [1 ]
Zhang, P. [1 ]
Zhang, Y. [1 ]
Wang, F. [1 ]
Lei, B. [1 ]
Gu, L. [1 ]
Yang, Y. [1 ]
Bai, J. [1 ]
Zhang, R. [1 ]
Wang, X. [1 ]
Ma, X. [1 ]
Wang, J. [1 ]
Wang, J. [1 ]
Wei, L. [1 ]
Zhang, J. [1 ]
Zang, X. [1 ]
Zhuang, Q. [2 ]
Fan, F. X. [2 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Hematol, Xian, Peoples R China
[2] Nanjing Legend Biotech, Nanjing, Jiangsu, Peoples R China
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S103
引用
收藏
页码：2 / 3
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Yamamoto, Chihiro
    Minakata, Daisuke
    Yokoyama, Daizo
    Furuki, Shuka
    Noguchi, Atsuto
    Koyama, Shunsuke
    Oyama, Takashi
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Hyodo, Kazuki
    Toda, Yumiko
    Ito, Shoko
    Nagayama, Takashi
    Umino, Kento
    Morita, Kaoru
    Ashizawa, Masahiro
    Ueda, Masuzu
    Hatano, Kaoru
    Sato, Kazuya
    Ohmine, Ken
    Fujiwara, Shin-ichiro
    Kanda, Yoshinobu
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
  • [2] HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
    Lebel, Eyal
    Asherie, Nathalie
    Kfir-Erenfeld, Shlomit
    Grisariu, Sigal
    Avni, Batia
    Elias, Shlomo
    Assayag, Miri
    Dubnikov-Sharon, Tali
    Zimran, Eran
    Shaulov, Adir
    Pick, Marjorie
    Cohen, Cyrille
    Stepensky, Polina
    Gatt, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S22 - S22
  • [3] Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
    Zhang, Lina
    Shen, Xuxing
    Yu, Wenjun
    Li, Jing
    Zhang, Jue
    Zhang, Run
    Li, Jianyong
    Chen, Lijuan
    ANNALS OF MEDICINE, 2021, 53 (01) : 1547 - 1559
  • [4] T cells carrying an anti-BCMA bb2121 chemical receptor in patients with refractory and/or relapsed multiple myeloma
    Sammut, Rinzine
    Richez, Valentine
    HEMATOLOGIE, 2019, 25 (03): : 134 - 134
  • [5] Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
    Jie, Jin
    Hao, Siguo
    Jiang, Songfu
    Li, Zonghai
    Yang, Min
    Zhang, Wenhao
    Yu, Kang
    Xiao, Jun
    Meng, Haitao
    Ma, Liyuan
    He, Mingxia
    Wang, Wei
    Huang, Xin
    Chen, Linjun
    Xing, Chongyun
    Yuan, Daijing
    Wang, Shasha
    Tao, Rong
    Dai, Lihui
    Ma, Hong
    BLOOD, 2019, 134
  • [6] Cardiovascular events during treatment with anti-BCMA chimeric antigen receptor T-cells in multiple myeloma
    Mathilde, Chanut
    HEMATOLOGIE, 2023, 29 (05): : 274 - 275
  • [7] Lenalidomide Enhances Anti-BCMA Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma
    Works, Melissa
    Soni, Neha
    Hauskins, Collin
    Sierra, Catherine
    Baturevych, Alex
    Jones, Jon
    Curtis, Wendy
    Johnstone, Timothy
    Kugler, David
    Jiang, Yue
    Hause, Ron
    Sather, Blythe Duke
    Salmon, Ruth
    Ports, Michael
    BLOOD, 2017, 130
  • [8] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [9] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
    Fang, Jiamin
    Zhou, Fuling
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083
  • [10] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
    Zhang, Xiaohui
    Ouyang, Chenxi
    Sun, Guofeng
    Liu, Hongfeng
    Qi, Junyuan
    Suo, Xiaohui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
12345